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ABSTRACT 
Background: Darbepoetin alfa is an erythropoiesis-stimulating glycoprotein 
with a -3-fold longer tl/2 and greater biological activity compared with recombi- 
nant human erythropoietin (rHuEPO). 
Objective: The objective of this study was to evaluate the efficacy and 
tolerability of long-term (24-week) darbepoetin alfa treatment in maintaining 
hemoglobin (Hb) concentrations in the target range of 10 to 13 g/dL in patients 
undergoing dialysis; the patients were switched from rHuEPO to a less-frequent 
dosing regimen of darbepoetin alfa without an increase in dose. 
Methods: In this Phase IIIb, open-label, multicenter study, patients with end- 
stage renal disease (ESRD) undergoing dialysis who were receiving rHuEPO BIW or 
TIW at baseline were switched to darbepoetin alfa QW; patients receiving rHuEPO 
QW were switched to darbepoetin alfa Q2W. Administration of darbepoetin alfa 
was by the same route as previous rHuEPO administration (IV or SC). Patients 
received arbepoetin alfa for 24 weeks, including a 20-week drug titration period 
followed by a 4-week, stable-dose evaluation period. The mode, dose, and frequen- 
cy of administration of darbepoetin alfa were compared with those of baseline 
rHuEPO. Tolerability assessment was based on spontaneous reporting and labora- 
tory tests (hematology, vital sign measurement, iron status, and biochemistry). 
Results: The study comprised 173 patients who were divided into 2 groups 
by route of administration (IV group, n = 146; SC group, n = 27). Mean (SE) ad- 
justed increases in Hb concentration from baseline to the evaluation period for 
patients receiving darbepoetin alfa QW were 0.94 (0.32) g/dL and 0.38 (0.30) g/dL 
for the IV or SC routes, respectively (P = 0.004 and NS, respectively). For pa- 
tients receiving darbepoetin alfa Q2W, the mean (SE) adjusted increases in 
Hb concentration were 0.08 (0.53) g/dL and 0.48 (0.35) g/dL for the IV and SC 
routes, respectively (both, P = NS). No significant differences in IV/SC dose ratio 
were observed between the 2 routes of administration. In addition, no increas- 
es in darbepoetin alfa dose were observed. The most commonly reported ad- 
verse events were hypertension (8 patients [5%]) and vascular access throm- 
bosis (4 [2%]). The incidence of treatment-related a verse vents was 6 (3%). 
Conclusions: Darbepoetin alfa effectively maintained Hb concentrations 
within the target range without an increase in dose, even at a reduced dosing 
frequency. Overall, darbepoetin alfa was well tolerated. (Curr Ther Res Clin Exp. 
2005;66:195-211) Copyright © 2005 Excerpta Medica, Inc. 
Key words: darbepoetin alfa, dialysis, efficacy, renal disease, rHuEPO, safety, 
tolerability. 
INTRODUCTION 
End-stage renal disease (ESRD) is a serious, life-threatening condition involving 
a full decline or failure in renal function. According to data from the National 
Association of Renal Disease Patient Registry, 17730 patients in Greece had a 
diagnosis of ESRD in 1993, and this incidence has increased by 12% each year 
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since. Of the patients with ESRD receiving dialysis, 87% undergo hemodialysis 
and 13% receive peritoneal dialysis. Only 150 renal transplantations are per- 
formed each year in Greece, thus emphasizing the importance of appropriate 
ambulatory care for patients undergoing dialysis) 
It is now well established that erythropoietin s the primary regulator of ery- 
thropoiesis and that decreased production of this glycoprotein by the kidney 
causes the anemia associated with ESRD. 2-4 Erythropoietin supports the sur- 
vival, proliferation, and differentiation of erythroid progenitor cells in the bone 
marrow. Recombinant human erythropoietin (rHuEPO), a glycoprotein with bio- 
logical and physical characteristics similar to endogenous erythropoietin, has 
become the standard of care worldwide for the treatment of anemia in patients 
with ESRD. Therapy with rHuEPO has been proved to increase red blood cell 
(RBC) mass and reduce the need for RBC transfusion. 5 
Darbepoetin alfa is an erythropoiesis-stimulating glycoprotein that works by 
the same mechanism as endogenous erythropoietin. Darbepoetin alfa has 2 
more sialic acid-containing carbohydrate chains compared with rHuEPO. 6-8 Due 
to its increased carbohydrate content, darbepoetin alfa has a tl/2 -3-fold longer 
than that of rHuEPO in patients with chronic renal disease. Due to this longer 
tu2 plus greater biological activity (as measured by hemoglobin [Hb] concentra- 
tion) compared with rHuEPO, darbepoetin alfa maintains effective control of Hb 
concentrations with less-frequent dosing compared with rHuEPO. 9-11 
In addition, evidence suggests that IV administration of darbepoetin alfa re- 
suits in greater increases in Hb concentration than SC administration. 12 Fur- 
thermore, the IV and SC dose requirements do not differ with darbepoetin alfa, 
contrary to experience with rHuEPO. 
The primary objective of this study was to assess whether unit dosing of dar- 
bepoetin alfa (rounding to the nearest prefilled syringe size) would maintain Hb 
concentrations in the target range of 10 to 13 g/dL, as recommended in the 
European Best Practice Guidelines for the Management of Anaemia in Patients 
with Chronic Renal Failure 13 in patients undergoing dialysis and switching from 
rHuEPO. The mode, dose, and frequency of administration of darbepoetin alfa 
were also compared with those of baseline rHuEPO. The secondary study 
objective was to assess the tolerability of long-term (24-week) darbepoetin alfa 
treatment in this patient population. 
PATIENTS AND METHODS 
This Phase Illb, 24-week, open-label clinical trial was conducted at 22 centers 
across Greece as part of a larger European collaborative ffort in order to eval- 
uate the efficacy and tolerability of darbepoetin alfa in controlling Hb concen- 
tration in patients with ESRD receiving peritoneal dialysis or hemodialysis. The 
study protocol was approved both by the institutional review board and the 
ethics committee at each participating clinical site. The research protocol was 
also evaluated and approved by the National Organisation for Medicines, 
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Athens, Greece, which is the Greek regulatory authority responsible for over- 
seeing clinical trials. Written informed consent was obtained from all patients 
prior to study initiation, as required by Greek law and suggested by the Inter- 
national Conference on Harmonisation-Good Clinical Practice guidelines. 14 
Patient Eligibility 
Patients who met all of the following criteria were eligible for participation in 
the study: age __.18 years; a diagnosis of ESRD; hemodialysis or peritoneal dialy- 
sis treatment for at least 6 months before screening; clinical stability; mean of 2 
measurements of the Hb concentration between 10 and 13 g/dL at all screening 
and baseline assessments; table rHuEPO SC or IV therapy QD, BIW, or TIW for 
at least 8 weeks before screening (stable was defined as <25% increase or 
decrease in weekly dosage over 8 weeks); adequate iron stores (serum ferritin 
concentration, _100 pg/L or transferrin saturation ~20%) during the screening 
period; availability for follow-up assessments; ability to comprehend the study 
instructions; and written informed consent for participation in the study. 
Patients who fulfilled any of the following criteria were ineligible for partici- 
pation in the study: treatment for grand mal epilepsy within the past 6 months; 
congestive heart failure (New York Heart Association class Ill or IV); uncon- 
trolled hypertension (defined as predialysis diastolic blood pressure ___110 mm Hg 
during the screening period); clinical evidence of current uncontrolled hyper- 
parathyroidism (eg, serum parathyroid hormone concentration >1500 pg/mL 
within the past 12 months); major surgery within 3 months before screening 
(excluding vascular access surgery); currently receiving antibiotic treatment 
for infection; current peritonitis; alanine aminotransferase and aspartate 
aminotransferase levels >2-fold the upper limit of normal; previously diagnosed 
HIV or chronic hepatitis B virus infection; clinical evidence of current malignan- 
cy (excluding basal cell or squamous cell carcinoma); RBC transfusion within 
12 weeks before screening or during the screening/baseline p riod or active 
hemorrhage; androgen therapy within 12 weeks before screening; systemic 
hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes, hema- 
tologic malignancy); myeloma; hemolytic anemia; or enrolled in or had not yet 
completed a period of at least 30 days since ending other investigational device 
or drug trial(s). Patients receiving other investigational gent(s), such as peri- 
toneal dialysate, could enter the study only after discussion and agreement 
with the sponsor. Patients were also ineligible if they had a psychiatric, addic- 
tive, or other disorder that compromised their ability to give truly informed 
consent or was likely to alter compliance; if they were pregnant (women of 
childbearing potential must have been using adequate contraception) or 
breastfeeding; or if they were anticipating or scheduled for living-donor enal 
transplantation. Any patient who required the following medications or treat- 
ments was withdrawn from the study: RBC transfusion(s) during the screening/ 
baseline period, rHuEPO therapy, androgen therapy, or any other investigational 
drugs throughout the study. 
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Treatment Assignment and Study Drug Administration 
Figure 1 shows the study design. After an initial 1-week screening period and 
a 1-week baseline period, patients were switched to darbepoetin alfa. In 
patients receiving rHuEPO BIW or TIW, the dosing frequency was reduced to 
QW. In patients receiving rHuEPO QW, dosing frequency was reduced to Q2W. 
The study drug treatment period was 24 weeks, which included a 20-week drug- 
titration period and a 4-week stable-dose evaluation period, followed by a 1-week 
end-of-study period. Due to the tl/2 of circulating RBCs (-60 days in patients 
with chronic renal disease), it was anticipated that the Hb concentration would 
reach equilibrium 20 to 24 weeks after switching from rHuEPO to darbepoetin 
alfa. 15 
The starting dose of darbepoetin alfa was determined by the patient's accumu- 
lated weekly dose of rHuEPO at the time of assignment of his or her study sub- 
ject number. Maintenance weekly dosing is initially half of the adjusted ose (3 x 
20 pg/kg IV body weight, which is later modified accordingly per patient for epo- 
etin beta 16 and 75-300 pg/kg IV with adjusted oses 50 pg/kg x 3 IV for epoetinum 
alfa17). A 200-IU: 1-pg ratio 18 was used initially for switching patients from rHuEPO 
to darbepoetin alfa. The Q2W dose of darbepoetin alfa was calculated by adding 
2 total weekly doses of rHuEPO and then converting to the corresponding darbe- 
I Written informed consent I 
Screening (1 week) I 
Baseline (1 week) I 
Eligible subjects I 
Darbepoetin alfa 
Change from rHuFPO to darbepoetin alfa based on current dosing and current route 
• rHuEPO BIW or TIW -~ Darbepoetin alfa QW 
• QW rHuFPO -~ Darbepoetin alfa Q2W 
Darbepoetin alfa administration (24 weeks) 
• Maintain hemoglobin within target range 
• Conduct tolerability assessments 
I End of study I 
Figure 1. Study design, rHuEPO = recombinant human erythropoietin. 
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poetin alfa dose. The calculated arbepoetin alfa dose was then rounded to the 
nearest of the available unit doses (10, 15, 20, 30, 40, 50, 60, 80, 100, 130, and 150 pg). 
Darbepoetin alfa was the only investigational agent in this study, and it was 
provided free of charge to the study patients. It was provided as a clear, color- 
less, human serum albumin (HSA)-free, sterile protein solution in prefilled 
syringes. The first dose of study drug was administered to the patient at the 
hemodialysis unit or the peritoneal dialysis clinic within 7 days of assignment 
of study subject number. Darbepoetin alfa was administered by the same route 
(IV or SC) as previous rHuEPO therapy. IV injections were administered through 
the venous dialysis line during the dialysis session, according to the dosing 
schedule. SC injections were administered at home by the patient or a nurse 
after proper training by the investigators. 
Study Visits 
Patients were to return to the clinic at weekly intervals during the dose-titration 
and evaluation periods for Hb concentration measurement. Iron status (se- 
rum ferritin concentration and transferrin saturation) was also assessed, at 
weeks 0 (baseline), 8, 16, and 24. A follow-up examination and assessments 
were performed at week 25 (study end). Blood samples were drawn by a nurse. 
Samples were processed on the same day based on current practice guidelines. 
Patients were instructed to visit the clinic for their assessments on the same 
day of the week as the first administration of study drug. This schedule was 
especially important for patients receiving hemodialysis, for whom assess- 
ments needed to be performed at consistent times in relation to their dialysis 
sessions. 
Efficacy Assessment 
The primary end point of the study was the change in Hb concentration 
between screening and baseline. Patients were divided into 2 groups by route of 
administration to analyze whether the route of administration affected dose 
requirements. The extent of unit dosing and frequency of administration (ie, the 
number of dose adjustments and dosing frequency changes) were also evaluated. 
Dose Adjustments 
During the 20-week dose-titration period, clinicians were to adjust he darbe- 
poetin alfa dose each time 2 consecutive Hb measurements were outside the 
target range of 10 to 13 g/dL. Hb concentrations were determined every other 
week, with concentrations outside the target range confirmed on repeat mea- 
surement within 7 days. If a patient had 2 consecutive Hb measurements above 
the target range (>13 g/dL), the darbepoetin alfa dose was decreased to the 
next-lower unit dose. Conversely, if the Hb concentration was below the target 
range (<10 g/dL) on 2 consecutive determinations, the dose was increased to 
the next-higher unit dose. Dose adjustments were to occur only in 1-step incre- 
ments on the list of allowable unit doses. 
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If a patient had 2 consecutive Hb concentrations above the target Hb range 
after the darbepoetin alfa dose had been decreased to 10 pg/wk, then the dosing 
frequency was reduced. Conversely, if a patient had 2 consecutive Hb concentra- 
tions below the target Hb range after the dose had been increased to 150 pg/wk, 
then the dosing frequency was increased. Dosing frequency was adjusted incre- 
mentally as follows: Q2W o QW o BIW ~ TIW. 
If the Hb concentration was >14 g/dL, it was immediately confirmed with a 
repeat measurement and darbepoetin alfa administration was discontinued 
until the Hb concentration decreased to within the target range. Darbepoetin 
alfa was then reinitiated at the next-lower unit dose. 
In patients who received ___1 RBC transfusion during the study, the dose- 
adjustment guidelines were not applicable. In this situation, doses were adjust- 
ed at the discretion of the treating physician, although the protocol did recom- 
mend that they be increased only if a patient's Hb concentration was <10 g/dL 
after receiving an RBC transfusion. 
If anemia was nonresponsive to darbepoetin alfa therapy, patients were 
assessed for common causes of poor erythropoiesis, including iron and/or vita- 
min deficiencies, hemorrhage, infection, and secondary hyperparathyroidism. 
If these potential causes of a poor response to therapy were excluded, the 
investigator could request hat a test for darbepoetin alfa seroreactivity be per- 
formed (all tests were to be performed by the study sponsor). 
Tolerability Assessment 
Tolerability was assessed using spontaneous reports of adverse events and 
the results of clinical laboratory tests (hematology, vital sign measurement, 
iron status, and biochemistry). The nature, frequency, severity, and relation to 
treatment of all adverse vents were evaluated. 
Statistical Analysis 
An intent-to-treat (ITT) analysis, which included all patients assigned a study 
subject number, was performed for the primary analysis of efficacy. If a patient 
discontinued the study prior to the evaluation period, the last available value was 
carried forward. Tolerability analyses were based on all patients who received 
~1 dose of darbepoetin alfa (per-protocol [PP] population). Statistical analyses 
were performed using SAS version 8.2 (SAS Institute, Inc., Cary, North Carolina). 
The analysis plan included the following: (1) the generation of descriptive statis- 
tics, including means (SD or SE); medians; ranges; interquartile ranges; and, where 
appropriate, 95% CIs; and (2) analytical statistics, including analysis of variance 
performed in the ITT population. P < 0.05 was considered statistically significant. 
RESULTS 
Study Population 
A total of 173 patients (98 men, 75 women) were recruited into the study (ITT 
population; IV, n -- 146; SC, n -- 27) and 172 received _~1 dose of the study drug 
201 
CURRENT THERAPEUTIC RESEARCH 
(PP population; IV, n = 145; SC, n = 27). One patient withdrew consent prior to 
receiving darbepoetin alfa. The demographic and clinical characteristics of the 
study patients are shown in Table I. All participants were white, ethnic Greeks, 
although race was not an eligibility or recruitment criterion. The mean age 
of patients enrolled in the study was 57.6 years; 111 patients (64%) were aged 
<65 years, and of the remaining 36%, 17 patients (10%) were aged ~75 years. 
One hundred forty-six patients (84%) were receiving hemodialysis and 
rHuEPO IV before the study. Overall, the most prevalent primary cause of renal 
failure was unknown (50 patients [29%]), followed by glomerulonephritis (45 
[26%]), hypertension (21 [12%]), and diabetes mellitus (17 [10%]). The mean 
(SD) baseline Hb concentration was 11.45 (0.70) g/dL in the IV group and 11.28 
(0.85) g/dL in the SC group. Although these 2 concentrations were similar, a 
numerically higher percentage of patients in the SC group had a depressed 
Hb concentration (<11 g/dL) (10 patients [37%]) compared with the IV group 
(36 patients [25%]) (Table I). 
At baseline, 70% of patients were receiving epoetin alfa and 30% were receiv- 
ing epoetin beta; 95% were receiving rHuEPO via prefilled syringes (mean 
dosage, 6405 U/wk). One hundred seven patients (62%) were receiving rHuEPO 
TIW, irrespective ofadministration route; 40 (23%), BIW; and 24 (14%), QW. After 
these patients were switched to darbepoetin alfa, 145 (84%) received therapy 
QW and 28 (16%) received therapy Q2W. 
Table II presents patient follow-up data. In addition to the patient who with- 
drew from the study before the initiation of treatment with the study drug, 17 
patients (10%) withdrew during the 20-week titration period. Reasons for dis- 
continuation were as follows: death (5 patients [3%]), renal transplantation 
(5 [3%]), loss to follow-up (4 [3%]), withdrawal of consent (2 [1%]), and hyper- 
tension (1 [1%]). Thus, 155 patients (90%) completed the titration and evalua- 
tion periods. 
Effectiveness 
During the dose-titration period, the original dosing schedule was un- 
changed or was adjusted only once in the majority of patients (125 [72%]). In 
22 patients (13%), the dose was titrated twice; in the remaining 26 (15%), 3 or 4 
adjustments were required to reach the optimal dose. However, when the dose 
was adjusted properly, 90% of the patients continued receiving darbepoetin alfa 
without requiring further dose modifications. The remaining 10% required fur- 
ther dose modifications due to idiosyncrasies. 
During the evaluation period, 5 of 28 patients (18%) assigned to receive dar- 
bepoetin alfa Q2W had the dosing frequency increased to QW. Of the 145 pa- 
tients assigned to receive darbepoetin alfa QW, 1 (1%) had the dosing fre- 
quency increased to BIW, and 1 (1%) to Q2W. 
During the evaluation period, 143 patients (83%) had Hb concentrations with- 
in the recommended range, whereas 12 patients (7%) had Hb concentrations 
outside the target range (lib <10 g/dL, 2 patients [1%]; Hb >13 g/dL, 10 patients 
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Table I. Baseline demographic and clinical characteristics of the study population 
(N = 173).* 
Route of Administration 
Characteristic IV (n = 146) SC (n = 27) 
Age, y 
Mean 57.7 56.9 
<65, no. (%) 94 (64) 1 7 (63) 
->65, t no. (%) 52 (36) 10 (37) 
->75, t no. (%) 14 (10) 3 (11 ) 
Sex, no. (%) 
Male 82 (56) 16 (59) 
Female 64 (44) 11 (41) 
Race, no. (%) 
White 146 (100) 27 (100) 
Body weight, mean (SD), kg 68.7 (14.5) 71.6 (12.5) 
Mode of dialysis 
Hemodialysis 146 (100) 18 (67) 
Peritoneal 0 (0) 9 (33) 
Primary cause of renal failure, no. (%) 
Unknown 44 (30) 6 (22) 
Glomerulonephritis 37 (25) 8 (30) 
Hypertension 19 (13) 2 (7) 
Diabetes mellitus 14 (10) 3 (11 ) 
Other urologic 12 (8) 2 (7) 
Polycystic renal disease 12 (8) 2 (7) 
Other 8 (5) 4 (15) 
Hb concentration 
Mean (SD), g/dL 11.45 (0.70) 11.28 (0.85) 
<11 g/dL~ 36 (25) 10 (37) 
_>11 g/dL 110 (75) 17 (63) 
Hb = hemoglobin. 
*Values were not tested for statistical significance. 
tpatients included in the group aged ->75 years are also included in the group aged ->65 years. 
~Depressed Hb concentration. 
[6%]). In the IV group, 118 of 146 patients (81%) had Hb concentrations _11 g/dL 
during this period versus 110 patients (75%) at baseline. Of the patients in the 
SC group, 21 of 27 patients (78%) had Hb concentrations >11 g/dL during the 
evaluation period versus 17 patients (63%) at baseline. A significant difference 
in the mean darbepoetin alfa starting dose was noted between the 2 routes of 
administration at baseline (P = 0.03), but no significant difference was observed 
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Table II. Recruitment and fol low-up of the intent-to-treat populat ion 
(N -- 173).* 
No. (%) 
Parameter of Patients 
Assigned a study subject number 173 
Withdrew prior to study drug administration 1 (1) 
Received ~1 dose of study drug 
(per-protocol population) 172 (99) 
Dose titration, weeks 1-20 
Started 172 (99) 
Discontinued t 1 7 (10) 
Completed 155 (90) 
Evaluation, weeks 21-24 
Started 155 (90) 
Discontinued 0 (0) 
Completed 155 (90) 
Total discontinued 18 (10) 
Total completed 155 (90) 
Died during survival follow-up 0 (0) 
*Percentages based on subjects allocated a study subject number. 
treasons for discontinuation were as follows: death (5 patients [3%]), renal transplantation 
(5 [3°/o]), loss to follow-up (4 [3%]), withdrawal of consent (2 [1%]), and hypertension (1 [1%]). 
during the evaluation period. Only 7 patients (4%) received RBC transfusions 
during the dose-titration/evaluation periods. 
The mean unadjusted increases in Hb concentration were 0.28 g/dL in the IV 
group and 0.17 g/dL in the SC group. For patients receiving darbepoetin alfa QW 
(IV, 131 patients; SC, 17 patients)--and after baseline Hb concentration, frequency, 
route, and dose of rHuEPO at entry and mode of dialysis were controlled--the 
mean (SE) adjusted Hb increases versus baseline were 0.94 (0.32) g/dL in the IV 
group (P = 0.004) and 0.38 (0.30) g/dL in the SC group (P = NS) (Table III and 
Figure 2). For those receiving darbepoetin alfa Q2W (IV, 15 patients; SC, 10 
patients)--and after the above variables were controlled--the mean (SE) adjust- 
ed increases in Hb concentration were 0.08 (0.53) g/dL and 0.48 (0.35) g/dL in the 
IV and SC groups, respectively; the differences were not statistically significant 
(Table Ill). Differences in dose requirements between baseline and the evalua- 
tion period are shown in Table IV and Figure 3. 
Tolerability 
No antibody formation was observed in any of the study participants (ie, no 
tests for seroreactivity to darbepoetin alfa were requested by the investi- 
gators). Five deaths (3%) were reported uring the study period. These deaths 
appeared to be the result of comorbid conditions consistent with this patient 
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Table III. Analysis of change in hemoglobin (Hb) concentrations between screening/ 
baseline and evaluation period by assigned frequency and route of darbe- 
poetin alfa administration. *t 
Route of Administration 
Frequency/Parameter IV SC 
QW 
No. of patients 131 $ 1 7 
Adjusted change in Hb, g/dL 
Mean (SE) 0.94 (0.32)§ 0.38 (0.30) 
95% CI 0.31 to 1.57 -0.22 to 0.98 
Q2W 
No. of patients 15 10 
Adjusted change in Hb, g/dL 
Mean (SE) 0.08 (0.53) 0.48 (0.35) 
95% CI -1.02 to 1.19 -0.25 to 1.20 
*Estimates for both routes of administration were derived from the same model. 
tAnalysis of variance adjusted for baseline Hb concentration, frequency, dose, and route of recombi- 
nant human erythropoietin administration at entry, and mode of dialysis. 
~P = 0.004 versus SC. 
§P = 0.004 versus baseline. 
2.0 
"- " 1.5 
e l  e -  
u o 1.0 ,m 
0.5 
e- U 
.-r 0 .0  
-0.5 I 
IV SC 
(n = 146) (n -- 27) 
Route of Darbepoetin Alfa Administration 
Figure 2. Changes in hemoglobin (Hb) concentration from baseline to evaluation 
period in patients receiving darbepoetin alfa QW (N = 173). *P -- 0.004 ver- 
sus SC. 
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Table IV. Dose requirements for darbepoetin alfa in the intent-to-treat population. 
Route/Parameter Baseline* Evaluation 
IV 
No. of patients 146 132 
Dose, Mg/wk 
Geometric mean 32.57 28.24 
95% CI t 29.60-35.83 24.95-31.97 
Median 30.00 30.00 
Range 10.00-150.00 3.80-160.00 
SC 
No. of patients 27 23 
Dose, Mg/wk 
Geometric mean 25.29 24.86 
95% CIt 10.00-80.00 10.00-80.00 
Median 25.00 25.00 
Range 20.65-30.97 19.44-31.79 
IV/SC ratio 
No. of patients 173 155 
Dose, Mg/wk 
Geometric mean 1.29 1.14 
95% CI t 1.02-1.63 0.83-1.55 
*Dose assigned at baseline. 
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Figure 3. Geometric mean weekly doses of darbepoetin alfa (N = 173). 
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population and were not considered by the attending physicians to be related 
to the study drug. Three of the 5 deaths were cardiovascular in nature (cardio- 
genic shock, cardiac arrest, and supraventricular tachycardia). One death was 
attributed to sepsis, and 1 death was due to cachexia. No deaths were reported 
during the evaluation or follow-up periods. 
Thirty-three patients (19%) reported adverse events, as follows: hyperten- 
sion (8 patients [5%]); vascular access thrombosis (4 [2%]); access hemorrhage 
and headache (3 [2%] each); fever, malaise, atrial fibrillation, angina pectoris, 
respiratory tract infection, fracture, and cholelithiasis (2 [1%] each); and in- 
flammation (1 [1%]). 
Overall, the incidence of treatment-related a verse events was 3% (6 pa- 
tients). The reported treatment-related adverse vents were hypertension (4 pa- 
tients [2%]), headache and insomnia (1 [1%]), and dry mouth (1 [1%]) (Table V). 
None of the adverse vents were considered severe. Hypertension led to study 
withdrawal in 1 case (1%). Tolerability analyses by age, sex, dialysis mode, 
baseline Hb concentration, and a subanalysis of administration route revealed 
no notable differences among these subgroups. There were no significant 
changes in laboratory data. Adequate iron stores were maintained according 
to European Best Practice Guidelines for the Management of Anaemia in Patients 
with Chronic Renal Failure 13 and the National Kidney Foundation Dialysis Out- 
comes Quality Initiative guidelines, 19 as mean transferrin saturation was >20% 
throughout the study and median serum ferritin concentration was >100 pg/L 
for all 24 weeks. Median serum ferritin concentration was 382 pg/L at base- 
line, 343 pg/L at week 16, 349 pg/L at week 24, and 341 pg/L at the end of the 
study. 
Table V. Treatment-related adverse events in the per-protocol pop- 
ulation (n = 172).* 
No. (%) 
Body System/Preferred Term of Patients 
Cardiovascular 
Hypertension 4 (2) t 
CNS/PNS 
Headache and insomnia 1 (1) 
Gastrointestinal 
Dry mouth 1 (1) 
Total 6 (3) 
CNS/PNS = central nervous system/peripheral nervous system. 
*None of the adverse events were considered severe. 
tOne of these patients (1%) withdrew due to this adverse event. 
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DISCUSSION 
This study found that in patients with ESRD receiving dialysis, Hb concentra- 
tions were effectively maintained within the recommended target range after 
switching from rHuEPO to a less-frequent dosing regimen of HSA-free darbepo- 
etin alfa without an increase in dose. 
At baseline, the mean Hb concentration of the study patients was _>11 g/dL in 
both the IV and SC groups. However, the proportions of patients who achieved tar- 
get Hb concentrations were 75% in the IV group and 63% in the SC group. Although 
these results exceed the European averages, 2°,21 they lag behind current clinical 
recommendations. The target of the European Best Practice Guidelines for the 
Management of Anaemia in Patients with Chronic Renal Failure 13 is for 85% of 
patients to achieve an Hb concentration of >11 g/dL in the maintenance phase of 
erythropoietic treatment. Thus, an improvement in the management of anemia 
due to ESRD would be beneficial for patients undergoing dialysis. 
In the present study, mean Hb concentrations were maintained at _>11 g/dL 
throughout the treatment and evaluation period, regardless of route or frequen- 
cy of administration of darbepoetin alfa. The percentages of patients with Hb 
levels _>11 g/dL were increased from 63% to 78% in patients receiving darbepo- 
etin alfa SC and from 75% to 81% in those receiving darbepoetin alfa IV. 
Similar to the findings of Locatelli et al, 12 the data in the present study sug- 
gest that IV administration results in greater increases in Hb concentration than 
SC administration. This may be attributed partially to the lower baseline Hb 
concentrations in patients receiving rHuEPO SC. However, the dosage IV/SC 
ratio that was found also suggests that there is no difference in dose require- 
ments for the different routes of administration. According to Locatelli et al, 12 
the pharmacokinetic characteristics of darbepoetin alfa compared with rHuEPO 
(eg, longer tl/2, which results in the ability to be administered less frequently) 
may explain why there was no difference in dose requirements between the IV 
and SC routes of administration. This finding offers dosing flexibility to physi- 
cians prescribing darbepoetin alfa. Due to its increased carbohydrate content, 
the level of darbepoetin alfa in the circulation remains above the minimum stim- 
ulatory concentration for erythropoiesis for longer than the equivalent molar 
dose of rHuEPO, allowing darbepoetin alfa to be administered less frequently to 
achieve the same biological response. 
Overall, HSA-free darbepoetin alfa was well tolerated in this study. The toler- 
ability data were consistent with that expected for patients with ESRD who 
undergo dialysis. The tolerability data are supported by previous reports sug- 
gesting that darbepoetin alfa is well tolerated, 22 with a safety profile similar to 
that of rHuEPO. 23 In the present study, 19% of patients reported adverse vents. 
Three percent of patients reported treatment-related a verse vents, the major- 
ity of which were due to the development of hypertension. The incidence of 
hypertension related to darbepoetin treatment reported in the literature ranges 
from 2% 13 to 30%. 24 Furthermore, 1 patient reported headache and insomnia 
and another patient reported ry mouth. 
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In the present study, Hb concentrations were maintained within a recom- 
mended target range with darbepoetin alfa at a less-frequent dosing schedule 
compared with rHuEPO. The ability to dose patients less frequently offers the 
advantage of convenience. A proper pharmacoeconomic evaluation is needed 
to estimate the potential cost-effectiveness of darbepoetin alfa in comparison 
with standard rHuEPO treatment. 
One limitation was that the eligibility criteria limit the ability to extrapolate 
the results of this study to the general population. Moreover, the study had 
further limitations, such as being open label and uncontrolled, with a small 
number of patients in the SC group. 
CONCLUSIONS 
In this study in patients with ESRD receiving dialysis who were switched from 
rHuEPO to darbepoetin alfa administered IV or SC, darbepoetin alfa effectively 
maintained Hb concentrations within the target range of 10 to 13 g/dL without 
the need for a dose increase, even at a reduced dosing frequency (Q2W). 
Overall, darbepoetin alfa was well tolerated. 
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